Prejex, Polybond collaborate to manufacture needle-less injections in India

Published On 2022-12-20 09:54 GMT   |   Update On 2022-12-20 09:54 GMT

Mumbai: Prejex Inc., a spin-off of Germany-based Prejex GMBH has entered into an agreement with Polybond, headed by Mr Adit Rathi of Rathi Group to manufacture needle-less injections.

This partnership has enabled shifting of the manufacturing capabilities of the German company from Berlin to Pune, for global distribution. The Prejex- Polybond factory will make needle-less injections for the entire world.

Advertisement
"The efforts of Mr. Niraj Khinvasara, CIO, World Trade Center, Pune, and Mr. Sagar Chordia, Chairman, World Trade Center Pune presented to Prejex a data-based analysis highlighting Pune as an industrial hub which includes over 250 German firms. The presentation focused on the decision of Mr. Maarten Stuut, MD of Prejex GMBH, and Mr. Harold Gerrits, Director of Global Sales and Distribution, to select India—especially Pune—as their preferred destination," the release stated.
Syringes and disposable needles are major contributors to toxic waste and their disposal cost is sky-rocketing. Trypanophobia (fear of needles) is a common factor leading to the reluctance of patients in drawing of blood and receiving vaccines or intravenous fluids.
With Prejex's entry, the pain factor is eliminated as the medicine is delivered subcutaneously through the skin which is an effective and reliable system. It also negates cross-contamination, ensuring safety and hygiene for doctors and patients alike. Being easy to use, even the patient can self-inject, reducing visits to the clinic and making healthcare more cost-effective. It is also convenient for customized doses and application of a variety of drugs. The shelf life of the drugs is considerably increased due to the novel COC polymer syringes and plasticizer. Besides, it drastically cuts down on the use of disposable syringes, most of which are used by diabetic patients, thus adding to the sustainability factor (about 5.5% of the global population or 422 million people are diabetic).
Two different models to be launched

1. The N-Jector Series—a single-dose disposable device: Here, the dose is 'pre-charged' or 'pre-filled' in an ampoule and the device can easily be packed and disposed of once the dose has been administered. The device and/or ampoule can both be stored in a refrigerator or at room temperature.

2. The Prejex Multi-Reusable Device goes up to 30,000 clicks and is ideal for home use and/or self-administration. It is compatible with pre-filled and non-filled ampoules that can be attached easily via a simple twist.

"Nearly 5% of the world is diabetic, that is, roughly 4.5-5 million people take 2 injections a day and companies like Prejex can alleviate pain and make life easier for patients. The medical sector is a critical segment for us. Prejex (Needleless Injections) is bringing to Pune a very innovative and strategic initiative by creating and fostering an ecosystem of medical innovation in India where we're sourcing distributors, too," said Niraj Khinvasara, CIO, World Trade Center, Pune.

"We are proud to be associated as the manufacturing partner for needleless injections for Prejex GmbH. This association is a true example of the 'Make in India' movement. Not only will European consumers get the benefit of European innovation combined by competitive Indian costs, such associations also accelerate the introduction of innovative products in the Indian market," said Adit Rathi, Managing Director, Polybond India Pvt Ltd.

Read also: Glenmark Pharma bags USFDA nod for high BP drug Nicardipine Hydrochloride

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News